- Homepage - GRAIL
GRAIL is a healthcare company innovating to solve healthcare’s most important challenges Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable
- Leadership Team - GRAIL
To pursue a mission like GRAIL’s, it takes all of us—a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world Our leadership team strives to push the boundaries of what is possible to achieve our bold mission
- Our History - GRAIL
In 2016, Illumina spun out a separate entity to focus on researching this incredible discovery, naming it GRAIL because the co-founders believed a simple blood test could be the “holy GRAIL” of cancer detection
- GRAIL to Present New Data on Galleri® and its Methylation Platform at . . .
GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
- Press Releases - GRAIL
GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research Annual Meeting 2023
- Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
GRAIL was founded by Illumina in 2016 and was spun out as a standalone company, powered by Illumina’s NGS technology, to develop state-of-the-art data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests
- GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
- GRAIL to Announce Fourth Quarter 2024 Financial Results
GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
|